Technology | 2009.12.10
InNexus And XERIS Announce Research Collaboration
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX.V:IXS) (www.ixsbio.com) and XERIS Pharmaceuticals, Inc. (www.xerispharma.com) announced today a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus’ Dynamic Cross Linking (DXL™) antibodies using XERIS’ proprietary formulation-injection technologies. “We see a need for an improved delivery system for antibodies that enables self injection of
For more information, please visit
http://www.businesswire.com/news/home/20091210005298/en
